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Method summary: 
Here we present a microarray nonlinear calibration (MiNC) method for quantifying antibody binding to the surface of protein 
microarrays. Calculated antibody binding is highly proportional to the antibody concentration in solution. When compared to 
previously described methods, MiNC significantly improved the linear dynamic range and reduced assay variation. More importantly, 
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We present a microarray nonlinear calibration (MiNC) method for quantifying antibody binding to the surface of protein 
microarrays that significantly increases the linear dynamic range and reduces assay variation compared with traditional ap-
proaches. A serological analysis of guinea pig Mycobacterium tuberculosis models showed that a larger number of putative 
antigen targets were identified with MiNC, which is consistent with the improved assay performance of protein microar-
rays. MiNC has the potential to be employed in biomedical research using multiplex antibody assays that need quantitation, 
including the discovery of antibody biomarkers, clinical diagnostics with multi-antibody signatures, and construction of 
immune mathematical models.
Protein microarrays are useful tools for 
simultaneously assessing antibody reactivity 
against a large number of targets using only 
a minute amount of sample. This multiplex 
capability makes microarrays attractive for 
evaluating antibody specificity and sensi-
tivity, measuring antibody response to 
vaccination or immunotherapy, screening 
disease-related antibody biomarkers in a 
high-throughput manner, and–potential-
ly–early diagnosis and treatment of cancer 
and infectious diseases with a signature 
comprising multiple antibody biomarkers 
(1–5). Binding is usually detected with 
a f luorescent dye-conjugated secondary 
antibody that binds the query antibody on 
the array. Current data assessments rely on 
direct comparison of signal intensities, which 
dramatically limits the ability to quantify 
the relationship between the fluorescent 
signal and the binding antibodies. Unlike 
traditional ELISA, which employs an 
independent standard curve to quantify the 
concentration of target antibodies, there is 
no common standard for the detection of 
antibodies binding to different targets on an 
array. Antibody affinities for their targets in 
serum vary, but currently, no method exists 
for objectively quantifying independent 
antibody concentrations. Improvements in 
the sensitivity and linearity of the dynamic 
range are also needed to aid in detecting 
low-abundance antibodies in clinical serum 
samples. The availability of such improve-
ments would broaden the applicability and 
acceptance of protein microarrays as routine 
biomedical research tools (6–8).
To address these concerns, we used 
nonlinear calibration to directly quantify 
the amount of query antibody binding the 
surface of protein microarrays using a newly 
developed microarray nonlinear calibration 
(MiNC) method. We validated this 
approach using the nucleic acid program-
mable protein array (NAPPA) developed 
in our laboratory (9–10). NAPPA uses a 
method for producing protein microarrays 
in which cDNAs encoding proteins are 
printed on the array and then converted 
to proteins by in vitro transcription/trans-
lation (IVTT). Translated proteins are 
captured to the surface by virtue of an 
epitope tag appended to the protein and a 
corresponding capture agent.
Materials and methods
Sera samples
The human serum was obtained from a 
healthy donor in the lab. The sera from 
guinea pig tuberculosis (TB) models were 
kindly provided by Dr. David McMurray, 
Texas A&M University, and included 
non-vaccinated/non-infected samples (n = 
6) and recombinant BCG (rBCG) vacci-
nated samples (n = 7). All sera were collected 
five weeks after respiratory challenge of the 
guinea pigs with M. tuberculosis H37Rv in 
an aerosol chamber.
Plasmid repository and high-throughput 
 DNA preparation
Sequence-verified, full-length cDNA 
expression Mtb plasmids in flexible donor 
vector systems were obtained from the J. 
Craig Venter Institute. Publicly available 
p53, c-jun, CYR AB, and PRDX4–3 
plasmids were obtained from the DNASU 
Plasmid Repository (http://dnasu.asu.edu/
DNASU/). These genes were subcloned 
into the T7-based mammalian expression 
vector pANT7_GST using LR recombinase 
(Invitrogen, Carlsbad, CA). High-throughput 
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preparation of high quality supercoiled 
DNA for cell free protein expression was 
performed as previously described (9). Briefly, 
expression plasmids were transformed into 
E.coli DH5α and grown in 1.5 mL terrific 
broth (Sigma-Aldrich, St. Louis, MO) with 
100 µg/mL ampicillin. DNA was purified 
with the NucleoPrepII anion exchange 
resin (Macherey-Nagel Inc., Bethlehem, 
PA) using a Biomek FX (Beckman Coulter, 
Inc., Fullerton, CA) automated laboratory 
workstation. Automated addition of all 
solutions was accomplished using a Matrix 
WellMate (Thermo Scientific, Hudson, NH) 
rapid bulk liquid dispensing instrument. 
Purified DNA was precipitated by addition 
of 40 µL NaOAc and 240 µL isopropanol 
followed by centrifugation at 4000× g for 30 
min. The DNA pellet was washed with 300 
µL 80% ethanol, centrifuged at 4000× g for 
30 min, dried, and resuspended in distilled 
water. For the p53 and multiplexed antibody 
assays, large quantities of p53, c-jun, CYRAB, 
and PRDX4–3 DNA were prepared using 
standard Nucleobond preparation methods 
(Macherey-Nagel Inc., Bethlehem, PA). All 
IgG standards and DyLight549-conjugated 
secondary antibody were purchased from 
Jackson ImmunoResearch Labs (West Grove, 
PA). Mouse anti-p53 antibody was obtained 
from Santa Cruz Biotech (Santa Cruz, CA). 
Mouse anti-c-jun antibody was obtained 
from Invitrogen. Mouse anti-CYRAB and 
anti-PRDX4–3 antibodies were obtained 
from SAIC-Frederick, Inc. (Frederick, 
MD).
Influence of zone effects and serum 
on IgG standards
To examine zone effects, mouse IgG standards 
were printed at four different locations on 
the amine-coated glass slide. The array was 
incubated with DyLight549-conjugated rabbit 
anti-mouse IgG antibody (10 µg/mL) for 1 h, 
followed by washing with PBST (PBS, 0.2% 
Tween) three times, then washing with water, 
and air drying. To examine the influence of 
serum on IgG standards, guinea pig IgG 
standards were printed on the slide and 
incubated with serum from ten guinea pigs 
(1:300 dilution) for 1 h. The resulting array 
was incubated with DyLight549 conjugated 
rabbit anti-guinea pig IgG antibody (10 µg/
mL) for 1 h, followed by washing with PBST 
3 times, washing once with water, and drying 
with air.
Anti-p53 antibody assay and multiplexed 
antibody assay with protein microarrays
Varying amounts of mouse IgG (0, 3, 10, 30, 
89, and 266 fmol) were printed on the amino-
modified slide along with different concen-
trations of p53 plasmid (316, 474, 711, 1067, 
1600, and 2400 ng/µL) (9–10). Briefly, the 
plasmid DNA was mixed with a master mix 
composed of capture antibody (50 µg/mL, 
anti-GST antibody, GE Healthcare Biosci-
ences, Piscataway, NJ), protein crosslinker (2 
mM, BS3, Pierce, Rockford, IL), and BSA (3 
mg/mL, Sigma-Aldrich). All samples were 
printed using a Genetix QArray2 (Genetix, 
Hampshire, UK) with 300 µm solid tungsten 
pins on amine-treated glass slides. With this 
approach, the anti-GST antibody, BSA, and 
plasmid DNA can be cross-linked to the 
amino groups on microarray spots. Arrays were 
protected from light and stored in an air-tight 
container at room temperature. The printed 
DNA was transcribed and translated in situ 
using previously published protocols (9–10). 
After IVTT and blocking with 5% milk with 
0.2% Tween 20, the resulting p53 array was 
incubated with different concentrations of 
anti-p53 antibody (0, 3, 8, 24, 74, 222, 667, 
and 2000 ng/mL) for 1 h and DyLight549-
conjugated rabbit anti-mouse IgG antibody 
(10 µg/mL) for 1 h separately. Then the slides 
were washed with PBST three times, once with 
water, and air-dried.
To perform multiple antibody assays, 1500 
ng/µL of c-jun, CYRAB, and PRDX4–3 
plasmids were printed on a slide parallel 
to mouse IgG standards. After IVTT, the 
resulting protein array was incubated with the 
antibody mixes comprising eight concentra-
tions of spiked mouse anti-c-jun, anti-CYRAB, 
and anti-PRDX4–3 antibodies in 1:300 diluted 
human serum. The spiked anti-c-Jun antibody 
concentrations were 0, 55, 165, 494, 1481, 
4444, 13333, and 40000 ng/mL The spiked 
anti-PRDX4–3 antibody concentrations were 
0, 27, 82, 247, 741, 2222, 6667, and 20000 
ng/mL. The spiked anti-CRYAB antibody 
concentrations were 0, 3, 8, 25, 74, 222, 667, and 
2000 ng/mL. Detection was performed with 
DyLight549-conjugated rabbit anti-mouse IgG 
antibody (10 µg/mL).
Analysis of guinea pig TB model  
serological response using protein  
microarrays
The serological response of guinea pig TB 
models was analyzed using high density 
microarrays consisting of 849 TB proteins 
and graded quantities of guinea pig IgG 
standards (0, 1.6, 5, 15, 44, and 133 fmol). 
To control the quality of TB NAPPA 
microarrays, the immobilized DNA plasmids 
were examined using PicoGreen stain (Invit-
rogen) diluted 1:1800 in Superblock solution 
(Pierce). The protein expression was examined 
using anti-GST monoclonal antibody (Cell 
Signaling, Danvers, MA) diluted 1:200 in 5% 
PBST milk. The immobilization of guinea pig 
IgG standards was examined with DyLight549 
conjugated donkey anti-guinea pig antibody 
(10 µg/mL). For the detection of antibodies in 
serum, the arrays were incubated with 2.5 mL 
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pooled sera from guinea pig TB models with 
and without rBCG vaccination, which was 
diluted 1:300 in 5% PBST milk. All incuba-
tions were carried out at 4°C for 16 h. Detection 
of the array was carried out using DyLight549-
conjugated donkey anti-guinea pig antibody (10 
µg/mL). This experiment was repeated three 
times using the same sera samples.
Data analysis
All slides were scanned with Tecan’s Power-
Scanner (Männedorf, Switzerland) and the 
images were quantitated using Array-Pro 
Analyzer, version 6.3 (Media Cyber-
netics, Bethesda, MD). All graphs were 
drawn using Excel 2007 (Microsoft Corp. 
Redmond, Washington) and OriginLab 
8.5 (OriginLab Corp., Northampton, 
MA). The nonlinear standard curve was 
either a four-parameter power curve
 
or a three-parameter logistic curve
fit according to the least-squares principle using 
XLfit 5.0 software (IDBS, Alameda, CA).
We computed intra-coefficient of variance 
(CV) coefficients for 6 proteins (p53 at concen-
trations of 711, 1067, and 1600 ng/µL, and jun, 
CYRAB, and PRDX4), for each of 2 repli-
cated experiments and 8 antibody concentra-
tions. The differences between MiNC and 
non-MiNC intra-CV coefficients for each 
protein were analyzed using a t-test to examine 
overall differences, and one-way ANOVA with 
a concentration factor to examine differences 
by concentration. For each protein and concen-
tration, we computed the inter-CV coefficient 
by calculating the CV of the means for the two 
experiments. We examined differences between 
the MiNC and non-MiNC inter-CV coeffi-
cients using a paired t-test.
To identify potential antibodies induced 
by rBCG vaccination, we first normalized raw 
signal intensities and the predicted antibody 
binding (fmol) by subtracting the background 
signal attributable to non-specific binding of 
TB antibodies, which was estimated by the first 
quartile of the nonspot control, and divided the 
result by the median background-adjusted value 
of proteins on the array. These values were then 
averaged over duplicate spots to obtain a single 
normalized value for each protein. To perform 
statistical analysis, the log-transformed data 
were analyzed using Significance Analysis of 
Microarrays (SAM) to select antibodies with 
higher levels in the rBCG group. SAM is a statis-
tical method originally used for selecting genes 
with significant changes in expression from 
DNA microarray data. SAM uses modified t-sta-
tistics to compare antibody levels and permu-
tation analysis to estimate false discovery rates 
(11). To perform the hierarchical analysis and 
draw the heat maps, the normalized data were 
transformed as previously described (12–13) and 
the analyses were performed using MultiExper-
iment Viewer 4.1 software (www.tigr.org).
Results and discussion
A general scheme for analyzing antibody 
assays with MiNC is shown in Figure 1. DNA 
plasmids encoding a relevant set of targets were 
printed on the array and expressed by IVTT 
in the usual fashion (Figure 1A, lower graph, 
green). In parallel, features containing purified 
IgG (from the same animal species as the 
primary antibody) were printed in measured 
and graded amounts on the array (Figure 1A, 
lower graph, left, brown). The resulting protein 
Figure 1. The detection of antibody using protein microarrays. (A) Schematic illustration of an antibody 
assay using microarray nonlinear calibration (MiNC). It consists of adding a series of different known 
amounts of IgG standards to an array. The IgG should match the species from which the primary anti-
body came (lower graph, brown). The IgG standards are used to construct a nonlinear standard curve 
(upper graph, left) to interpolate the amount of IgG antibodies that bind to the surface of each protein 
spot after antibody incubation (upper graph, right), which is calculated and represented in fmol (red). 
The detection is performed with fluorescent-dye conjugated secondary antibody. SFI is the sum of fluo-
rescent intensity within each protein spot (black). (B) Fluorescent images of the detection of different 
concentrations of mouse anti-p53 antibody. The left sub-array shows the mouse IgG standards (0, 3, 
10, 30, 89, 266 fmol) and the right sub-array comprises different concentrations of p53 DNA plasmids 
(316, 474, 711, 1067, 1600, and 2400 ng/µL) in six replicates used to express proteins by the nucleic 
acid programmable protein array (NAPPA) method. The detection was performed with DyLight549-
conjugated rabbit anti-mouse IgG secondary antibody.
Figure 2. Influence of zone effect and serum on IgG standards. (A) Fluorescent image of mouse IgG stan-
dards at different locations of the slide; (B) Comparison of fluorescent signal intensity of four IgG standards; 
(C) and (D) are the comparisons of the signal intensity and calibration curve of guinea pig IgG standard after 
incubation with sera from each of ten guinea pigs. The detection was performed with DyLight549-conjugat-
ed rabbit anti-mouse IgG antibody and rabbit anti-guinea pig IgG secondary antibody, respectively.
(x)=a(1-e-bx)c f
f (x)=axb+cxd 
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microarrays were probed with either antibodies 
or serum expected to recognize one or more 
of the protein targets on the array (Figure 1A, 
lower graph, right, brown). These were then 
visualized using the appropriate secondary 
anti-IgG antibody coupled to a fluorescent 
dye. In addition to binding any primary 
antibodies captured by target antigens, the 
secondary antibody also bound to the series of 
IgG molecules. Then we fit a nonlinear curve to 
the signals from the labeled secondary antibody 
to the IgG standards (Figure 1A, upper graph, 
brown). By comparing the target feature signals 
(black) with the nonlinear IgG calibration 
curve, we interpolated the amount of antibody 
that bound to the surface of each spot, which 
was calculated and represented as fmol of bound 
antibodies (red).
Linear calibration using IgG standards has 
been used previously as an indirect fluorescent 
detection method for antigen microarrays in 
infectious disease testing. However, the use 
of a linear standard curve limited the range 
of detection to approximately one order of 
magnitude; signals outside this range were 
not reliably quantified (14–15). The use of a 
nonlinear curve may ameliorate this limitation 
significantly (16), but optimally fitting a 
nonlinear curve to data is a non-trivial problem, 
with solutions depending not only on the data 
themselves (e.g., number of points, number of 
unique x values, variability), but also on the 
desired shape, smoothness, and intended use 
of the curve. Thus, no single approach to curve-
fitting will be appropriate for all applications. In 
the context of calibration, fixed-form methods 
using logistic and power curves are commonly-
used (17–19). Alternative methods based upon 
flexible splines or hierarchical models have also 
been proposed (20–21). The ideal calibration 
curve will fit the data well, be smooth enough to 
be insensitive to experimental errors, and retain 
the true zero point. Visual inspection of the 
calibration curves is crucial to assess both fit and 
smoothness. Findlay and Dillard discuss several 
important issues with calibration, including 
different calibration models, methods to fit 
models, and methods to assess model fit and 
array design (17). Retention of the true zero 
point is critical to ensure that the calibrated 
data remain on a ratio scale, which is a required 
property in order for the CV to be an appro-
priate measure of error. In our experiments we 
have found that power and logistic functions, 
parameterized using three to four parameters 
and estimated according to the least-squares 
principal, typically yield smooth curves that fit 
the data well. Specifically, in this work we have 
used both a four-parameter power curve
and a three parameter logistic curve
However, we caution that other experimental 
data and experimental conditions may require 
different approaches to generate appropriate 
calibration curves, and that calibration curves 
should always be inspected visually to ensure 
adequate fit and smoothness.
We first investigated the quality of the IgG 
calibration features on the NAPPA platform. 
We examined whether the IgG standard was 
affected by the printed slide position and found 
that all of the spots on the slide exhibited 
excellent feature morphology with an average 
variation of 14% (range: 3%–27%) (Figure 2, 
A and B). We also compared the IgG standard 
following incubation with serum from ten Mtb 
challenged guinea pigs  individually and found 
an average variation of 10% (range: 6%–14%) 
(Figure 2, C and D).
To evaluate quantitative performance, we 
chose p53 and mouse anti-p53 antibody as a 
model. Figure 1B exhibits an increase in the 
fluorescent signals of both the IgG standards 
at the left and expressed p53 proteins at the 
right side of each array as antibody concen-
tration increases. The signal intensities at 
eight anti-p53 antibody concentrations were 
measured against DNA plasmids encoding 
p53 at concentrations of 711, 1067, and 1600 
ng/µL (Figure 3, A and B, Supplementary 
Figure S1), which covers the typical range of 
DNA plasmids printed. The graphs show that 
the raw signal intensity (black) increased with 
increasing anti-p53 antibody concentration in 
a nonlinear fashion. Although the dynamic 
ranges of fluorescent-based antibody assays 
typically cover three orders of magnitude, the 
linear dynamic range of the raw signals, within 
which changes in antibody concentration can 
Figure 3. Comparison of antibody assays with and without MiNC. (A) and (B) The detection of anti-p53 
antibody using p53 DNA plasmid concentrations of 1067 and 1600 ng/µL to produce p53 protein lo-
cally. The y-axis and x-axis are the signal intensity (black) and the fmol (red) from the blank controls, 
respectively. (C) and (D) The comparison of intra-CV and inter-CV using raw signal intensity (black) 
and microarray nonlinear calibration (MiNC)-calibrated intensity (red), respectively. Each boxplot rep-
resents the distribution of coefficient of variance (CV) values across three p53 plasmid concentrations 
(711, 1067, and 1600 ng/µL) in which the bottom edge, top edge, and middle line correspond to the 
minimum, maximum, and median values, respectively. (E) and (F) Multiplex detection of antibodies in 
human serum without and with MiNC. The graphs were drawn using raw signal intensity (E) and MiNC-
calibrated intensity (F). The error bars represent the standard deviations. The R2 was calculated to show 
the linear relationship of antibody concentration to calibrated antibody levels using MiNC.
A B
C D
E F
(x)=a(1-e-bx)c f
f (x)=axb+cxd 
.
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be accurately measured, was only about one 
order of magnitude. Thus, changes in antibody 
concentration outside of this range were not 
readily measured by raw fluorescence intensity. 
However, after estimating the amount of bound 
antibody (red color) by calibrating with a four-
parameter power curve
we found a linear relationship over 2.5–3.0 
orders of magnitude for the assay (red) with 
an R2 of 0.99.
We also compared the signal variation for 
raw intensity (Figure 3, C and D, black) and 
calibrated intensity (Figure 3, C and D, red) 
within a single experiment (intra-CV) and 
between different experiments on different 
days (inter-CV). The results showed that 
MiNC improved both the intra-CV (Figure 
3C) and inter-CV (Figure 3D) at all concen-
trations of anti-p53 antibody from 0 ng/mL 
to 2000ng/mL. With MiNC, the average 
intra-CV decreased from 9% to 4%, and the 
average inter-CV decreased from 18% to 
8% (Table1). We also calculated the lowest 
concentration of detection limit (LOD) for 
the anti-p53 antibody based on the mean value 
of negative controls plus three standard devia-
tions. The results showed that the LOD with 
MiNC ranged from 0.14 to 0.30 ng/mL, which 
was almost no different from the LOD without 
MiNC. 
To further expand these results and to test 
whether the presence of serum affected the 
outcome, we spiked eight different concen-
trations of mouse anti c-jun, anti-CYRAB, 
and anti-PRDX4–3 antibodies in 1:300 
diluted human serum (22). Using the same 
method, we found that predicted antibody 
binding was proportional to the change of 
antibody levels with R2 values of 0.99 for all 
3 antibodies (Figure 3, E and F). The average 
intra-CV decreased from 10% to 4% and the 
inter-CV had no change: 10% before and after 
calibration with MiNC, respectively (Table 
2). The LOD also did not change. From this 
equation describing antibody-antigen inter-
action
we know that the amount of antibody-antigen 
complexes formed on the microarray spots is 
proportional to the antibody concentration 
because the reaction volume and number of 
antigens are fixed and the Kd is dependent on 
the affinity of the antibodies. This is consistent 
with our results and shows the feasibility of 
antibody quantification with MiNC on protein 
microarrays. In comparison with previously 
developed methods to improve the assay perfor-
mance of protein microarrays and antibody 
microarrays, such as two-color Fab labeling 
or internally controlled systems (23–24), 
MiNC not only significantly improved the 
linear dynamic range, but also reduced assay 
variation. More importantly, it has the ability 
to quantify hundreds of antibodies binding to 
the protein microarray simultaneously.
To demonstrate the feasibility of using 
MiNC with high density protein microarrays 
Table 1 Comparison of the performance of anti-p53 antibody assay without and with MiNC
p53 DNA 
Plasmids
(ng/µL)
LOD (ng/mL)  Dynamic range (ng/mL)  Intra-CV(%)*  Inter-CV(%)*
MiNC  MiNC  MiNC  MiNC
- +  - +  - + p-value  - + p-value
711 0.41 0.30  0.41 - 667 0.30 - 667  10 4 <0.001  18 9 0.191
1064 0.15 0.14  0.15 - 667 0.14 - 667  10 5 <0.001  22 9 0.055
1600 0.21 0.14  0.21 - 2000 0.14 - 2000  7 4 0.001  12 6 0.230
AV       9 4   18 8  
*The intra-CV and inter-CV were calculated as the average CV across eight anti-p53 antibody concentrations.
Table 2 Comparison of the performance of multiplexed antibody assay without and with MiNC
Name
LOD (ng/mL)  Dynamic range (ng/mL)  Intra-CV(%)*  Inter-CV(%)*
MiNC  MiNC  MiNC  MiNC
- +  - +  - + p-value  - + p-value
CYRAB 0.4 0.4  0.4 - 2000 0.4 - 2000  9 3 <0.001  15 10 0.278
c-Jun 57.2 22.2  57.2 - 40000 22.2 - 40000  9 3 <0.001  6 10 0.235
PRDX4–3 5.6 3.4  5.6 - 20000 3.4 - 20000  12 4 <0.001  10 10 0.944
AV       10 4   10 10  
*The intra-CV and inter-CV were calculated as the average CV across eight antibody concentrations.
Figure 4. Quality control of NAPPA microarrays with 849 TB genes. Expression clones encoding the 
target proteins fused to a C-terminal GST tag were printed along with a polyclonal anti-GST antibody 
in duplicate on the nucleic acid programmable protein array (NAPPA) surface. (A) DNA capture was 
confirmed by PicoGreen (PG) staining (DNA). (B) In situ protein expression and capture were assessed 
by GST detection using a monoclonal antibody (protein). The correlation of duplicate spots within 
one slide (C) and between two different slides (D) is 0.96 and 0.81, respectively (GST color code: 
red>orange>yellow>green>blue).
f (x)=axb+cxd 
[AgAb]=(
[Ag]
kd
)[Ab] 
A B
D
C
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for the discovery of antibody based biomarkers, 
we fabricated protein microarrays consisting 
of 849 TB proteins (Figure 4). We analyzed 
the immunological response to these proteins 
using pooled sera from Mtb challenged guinea 
pigs with (n = 7) and without (n = 6) immuni-
zation with rBCG, a recombinant mycobac-
terial vaccine. The experiment was repeated 
three times. The raw data were normalized by 
subtracting the background, estimated by the 
first quartile of nonspot controls (features with 
the same chemistry but not producing protein), 
and dividing by the median excess intensity of 
non-control spots. Calibrated data were calcu-
lated using a three-parameter logistic curve
 
and normalized similarly. We applied SAM (11) 
to both the raw and calibrated log-transformed 
normalized data to identify the antibodies 
elevated in rBCG vaccinated guinea pigs 
compared with the non-vaccinated group. With 
a SAM delta value of 1.9 and an estimated false 
discovery rate of 0, the raw intensity enabled the 
identification of 16 antibody candidates (Figure 
5A). Using the calibrated data, 35 candidates 
were identified (Figure 5B and Supplementary 
Table S1). Of note, 10 candidates identified 
from the raw intensity data were also identified 
from the MiNC calibrated data. Similar results 
were found using Welch’s t-test in place of SAM 
analysis. (Supplementary Figure S2 and Supple-
mentary Table S2). Although it is unknown 
whether the set of candidates from MiNC is 
actually better than the set without MiNC, the 
identification of a larger number of candidates 
with MiNC is consistent with the improved 
performance of antibody assays with MiNC 
(Figure 5C). These results reveal that MiNC 
can be used with protein microarrays and 
has the potential to identify more antibody 
biomarker candidates.
The ideal antibody assay must be sensitive, 
reliable, and able to detect signals across a large 
dynamic range. In this work, we addressed 
these issues using the developed MiNC method 
and showed its advantages for antibody assays 
with protein microarrays. First, in traditional 
sandwich ELISA or multiplexed sandwich 
immunoassays, nonlinear fitting curves from 
protein standards are routinely used as a quanti-
fication method. However, non-specific binding 
between capture and secondary detection 
antibodies limits the number of targets that 
can be accurately quantified to less than 30–50 
(25–26). This limitation can be overcome with 
protein microarrays, in which high quality 
fluorescein labeled detection antibodies can 
specifically recognize all antibodies captured 
by their corresponding antigens on microarray 
spots (27). The binding of antibodies to their 
targets is clearly nonlinear. Linear curve 
fitting will provide accurate predictions in 
the mid-range of the binding curve where it 
is most linear, but predictions will fail at the 
high and low ends of the curve. Thus, utilizing 
a nonlinear curve to resolve the linear limit of 
the assay enables accurate interpolation of signal 
intensities for quantifying binding antibodies 
at the extreme ends of the curve, effectively 
expanding the range of accurate predictions. 
With MiNC, we not only are able to show 
whether an antibody biomarker increased with a 
p value but also to provide detailed information 
regarding the change of biomarker abundance 
during disease development. This information 
is especially valuable for the early detection and 
therapeutic treatment of a disease.
Second, calibration increased the linear 
portion of the dynamic range of the antibody 
assay, which facilitated better comparison 
of data across different serum samples (28). 
Linearity is limited without MiNC because 
the slope of the standard curve changes with 
the increased signals from raw fluorescent 
intensity.
Third, the multiplex antibody assay using 
MiNC has better reproducibility due to its 
Figure 5. Identification of antibodies with significant elevation in rBCG vaccinated guinea pigs us-
ing the SAM algorithm. (A) and (B) Data from antibodies with significantly increased levels in rBCG 
vaccinated animals compared with the non-vaccinated guinea pigs group without and with MiNC, re-
spectively. Serological analysis was performed using protein microarrays displaying 849 TB proteins 
and probed with serum from M. tuberculosis challenged guinea pig TB models without (NON) and 
with rBCG immunization. The experiment was repeated three times and the statistical analysis was 
performed using the significant analysis for microarray (SAM) algorithm with a delta value of 1.9 and an 
estimated false discovery rate of 0. The color from blue to black to yellow corresponds to the normal-
ized value from low to median to high. The gray is the signal below the first quartile of nonspot controls. 
(C) Graphs showing the percentage of noise contributed by duplicate spots in high-density TB protein 
microarrays. The x-axis represents all genes in the array; y-axis represents variations in signal intensity 
between the duplicates of each gene.
(x)=a(1-e-bx)c f
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smaller variation within arrays. Decreased 
variation also improves the subsequent statistical 
analysis and can lead to discovery of potential 
antibody biomarkers that otherwise would be 
missed because of background noise. These 
putative targets increase opportunities for 
validation by independent sera samples and 
confirmation as real biomarkers (29).
And finally, we found that the influences 
of printed slide position and different sera on 
IgG standards were minimal, indicating that 
IgG standards are robust and independent of 
the assay and that the standard curve can be 
reliably reproduced. The low cost, easy avail-
ability, and good quality of IgG molecules 
make them ideal standards for predicting the 
number of binding antibodies and comparing 
data between different experiments or even 
data originating from different labs.
MiNC helps correct for many variations 
introduced during processing of the arrays, 
including decreasing variations in reagent 
preparation, array processing, and detection. 
However, it cannot prevent variation 
from array fabrication; performance will 
always depend on the quality of the fabri-
cated protein microarrays. Printing IgG 
standards in parallel with the samples and 
the calibration process will slightly increase 
the time and number of steps needed for array 
preparation and data processing, especially if 
primary antibodies come from more than one 
isotype, such as the simultaneous detection of 
IgG, IgM, and IgA antibodies (30).
Altogether, we expect that the cumulative 
results will provide scientists with a new 
appreciation for antibody assays with protein 
microarrays. MiNC has the potential to be 
widely employed in biomedical research with 
multiplexed antibody assays requiring quanti-
tation, such as in the discovery of antibody 
or auto-antibody biomarkers, clinical 
diagnostics with multi-antibody signatures, 
and construction of immune mathematical 
models with system biology.
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